Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock

Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

By Mary Caffrey

April 29th 2025

senior scientist | Image credit: Ohio State University

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

By Mary Caffrey

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 24th 2016

Brain Tumors Most Common Cause of Cancer Deaths in AYAs

Surabhi Dangi-Garimella, PhD

A collaborative study conducted across cancer treatment centers in the United States has identified malignant brain tumors as the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39 years.

February 24th 2016

What We're Reading: Drug Makers File Incomplete Side Effects Reports

AJMC Staff

What we're reading: drug makers are not reporting complete information about side effects; Johnson & Johnson will pay $72 million to the family of a woman who blamed her ovarian cancer on talcum powder; and Maine and Utah make new attempts at expanding Medicaid.

February 24th 2016

Investment in the National Cancer Moonshot - Hit or Miss?

Priyam Vora

Experts and biological researchers aren’t completely convinced with the president's cancer moonshot initiative and the released budget.

February 24th 2016

Income Inequality Contributes to Pediatric ALL Relapse

Surabhi Dangi-Garimella, PhD

Survival in children with acute lymphoblastic leukemia could be significantly influenced by their family’s socioeconomic status, a new study published in Pediatric Blood and Cancer has found.

February 23rd 2016

COA's Ted Okon to Discuss Oncology Trends in AJMC's February Tweetchat

Ted Okon, MBA, of the Community Oncology Alliance, will participate in a tweetchat with The American Journal of Managed Care on February 29, 1-2 pm ET, to discuss the 340B program, payment reform, the Oncology Medical Home, and more.

February 23rd 2016

BMJ Finds No Link Between Incretins and Pancreatic Cancer, but Debate Likely to Continue

Mary Caffrey

BMJ's study found no link bewteen incretin-based drugs and pancreatic cancer but said because of the latency of the cancer, adverse effects would have to be watched.

February 23rd 2016

Cancer-Specific Racial Disparities Persist Despite Overall Progress

Surabhi Dangi-Garimella, PhD

A new report by the American Cancer Society points to disparities in cancer survival between whites and blacks for certain cancers, although the reasons for these differences remain unconfirmed.

February 22nd 2016

Clinician Support Tool for Discussions on Cancer Care Costs

Surabhi Dangi-Garimella, PhD

The online tool includes worksheets for the most commonly used cancer treatment protocols that care providers can directly access through the electronic health record.

February 22nd 2016

Expanded Label for Palbociclib in Relapsed, Advanced Breast Cancer

Surabhi Dangi-Garimella, PhD

The supplemental new drug application submitted by Pfizer, the drug's manufacturer, included phase 3 results from the PALOMA-3 trial.

February 22nd 2016

What We're Reading: Seeking a Moratorium on New Drug Ads

AJMC Staff

What we're reading, February 22, 2016: new legislation proposes placing a 3-year moratorium on advertising newly approved drugs; the prevalence and incidence of stroke among young adults has increased significantly; and more women with breast cancer are choosing outpatient mastectomies.

February 22nd 2016

Procedural Vote May Push Califf Through to Lead the FDA

Surabhi Dangi-Garimella, PhD

Support from at least 60 senators during today's procedural vote will ensure a final confirmation vote for Robert Califf, MD, likely Tuesday.

February 20th 2016

This Week in Managed Care: February 20, 2016

This week's top managed care stories included the release of 7 core sets of quality measures, more evidence that value-based insurance design works to lower costs, and the FDA assigns breakthrough designation to AstraZeneca's PD-L1 inhibitor.

February 19th 2016

Patients With Head and Neck Cancer Face Lifestyle Alterations and Poor Survival

Surabhi Dangi-Garimella, PhD

Two studies presented at the ongoing 2016 Multidisciplinary Head and Neck Cancer Symposium report on financial hurdles faced by patients diagnosed with head and neck cancer that result in lifestyle modifications, advanced disease, and worse outcomes.

February 18th 2016

Immuno-Oncology Agents Are Not Above Resistance, Study Shows

Surabhi Dangi-Garimella, PhD

A new study, published in Nature Communications, has delineated a mechanism that could help explain the resistance that is emerging with the new immuno-oncology agents such as PD-1 and PD-L1.

February 17th 2016

Task Force Recommends Post-Operative Colonoscopy Over Endoscopy for Improved Outcomes in CRC

Surabhi Dangi-Garimella, PhD

A Task Force composed of gastroenterology specialists, with a special interest in colorectal cancer, has released updated recommendations urging post-operative colonoscopy instead of endoscopy to improve survival.

February 17th 2016

Anti—PD-L1 Agent, Durvalumab, Gets Breakthrough for Bladder Cancer

AJMC Staff

Durvalumab is being developed for the treatment of PD-L1—positive patients with inoperable or metastatic urothelial bladder cancer

February 17th 2016

AJMC's Evidence-Based Oncology Takes a Fresh Look at Massive Impact of Immuno-Oncology

Evidence-Based Oncology, the multistakeholder publication of The American Journal of Managed Care devoted to cancer care, revisits the rapidly evolving field of immuno-oncology in its current issue. While one author calls the clinical impact of “tsunami proportions,” the healthcare system is grappling with how to pay for these therapies.

February 16th 2016

CMS' Core Oncology Measures - A Work in Progress

Surabhi Dangi-Garimella, PhD

CMS, in collaboration with a working group of national organizations, has developed a set of Medical Oncology Measures to improve quality of care and avoid redundancy for providers of care.

February 16th 2016

Humana Uncommitted on Cologuard Test, Faces Lawsuit

Surabhi Dangi-Garimella, PhD

A noninvasive colorectal cancer screening test manufactured by Exact Sciences, which received CMS coverage within months of its FDA approval, is not included under Humana’s coverage policy

February 15th 2016

Shortcomings of Written Informed Consent Forms

Jackie Syrop

Relatively simple improvements could increase patient satisfaction and potentially improve the important process of imparting patient information during enrollment of cancer patients into clinical trials.

February 15th 2016

Study Identifies Biomarkers and Potential Targets in Obesity-Associated Cancers

Surabhi Dangi-Garimella, PhD

Inhibiting the PIGF/VEGFR-1 signaling regressed tumor growth in obese, but not in lean mice, the author report.

February 12th 2016

Socioeconomic Status an Important Determinant of HPV Vaccination

Surabhi Dangi-Garimella, PhD

A study published in Cancer Epidemiology, Biomarkers & Prevention has identified geographic and ethnic factors as an important determinant of vaccinating against the human papillomavirus.

February 12th 2016

UK Regulators Perceive Value of Nivolumab in RCC

AJMC Staff

Patients with advanced kidney cancer in the UK now have access to nivolumab through an early access scheme.

February 12th 2016

FDA Update in Oncology, February 2016

Surabhi Dangi-Garimella, PhD

Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

February 12th 2016

Managed Care Updates in Oncology, February 2016

Surabhi Dangi-Garimella, PhD

A summary of updated breast cancer screening guidelines, MEDPAC recommendations for 340B, and disparity in survival of young patients with Hodgkin lymphoma.

February 11th 2016

Does Genetic Testing Impact Treatment Decisions in Breast Cancer?

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology found that the knowledge of genetic risk influenced surgical treatment decisions in women younger than 40 years who were diagnosed with breast cancer.

February 11th 2016

Cancer MoonShot 2020 Proposes a Collaborative Precision Cancer Care Model

Surabhi Dangi-Garimella, PhD

At the annual JP Morgan Healthcare Conference, Patrick Soon-Shiong, MD, introduced Cancer MoonShot, his vision for a coalition to improve cancer outcomes. His claims on federal support for the project, however, stirred some controversy.

February 11th 2016

Shaping the Future of Immuno-Oncology

Joseph Alvarnas, MD

While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.

February 11th 2016

Study Compares Filgrastim vs Tbo-Filgrastim in Patients With Myeloma

Priyam Vora

While there are no significant differences in the results between filgrastim and tbo-filgrastim in a clinical setting, tbo-filgrastim offers significant cost savings over filgrastim.

February 10th 2016

New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE

Surabhi Dangi-Garimella, PhD

Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.

...

107 108 109 110 111 112 113 114 115

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions